BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities.
Hu
Chih-Bo
CB
Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Chen
Ching-Ping
CP
Yeh
Teng-Kuang
TK
Song
Jen-Shin
JS
Chang
Chi-Yen
CY
Chuu
Jiunn-Jye
JJ
Tung
Fei-Feng
FF
Ho
Pei-Yin
PY
Chen
Tung-Wei
TW
Lin
Chi-Hung
CH
Wang
Min-Hsien
MH
Chang
Kai-Yen
KY
Huang
Chen-Lung
CL
Lin
Heng-Liang
HL
Li
Wen-Tai
WT
Hwang
Der-Ren
DR
Chern
Jyh-Haur
JH
Hwang
Ling-Ling
LL
Chang
Jang-Yang
JY
Chao
Yu-Sheng
YS
Chen
Chiung-Tong
CT
D000284:Administration, Oral; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D050256:Antimitotic Agents / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D004285:Dogs; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D007942:Leukemia, Experimental / Q000188:drug therapy; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008870:Microtubules / Q000737:chemistry / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D013844:Thiazoles / Q000494:pharmacology*
D020533:Angiogenesis Inhibitors; D050256:Antimitotic Agents; D000970:Antineoplastic Agents; D007211:Indoles; C555061:N-(3-methyl-5-isothiazolyl)-2-1-((3-methyl-5-isoxazolyl)methyl)-1H-3-indolyl-2-oxoacetamide; D013844:Thiazoles